Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Aims to enhance capital efficiency, improve operational focus and position each business to independently create and capture value.
April 6, 2026
By: Charlie Sternberg
Associate Editor
Scinai Immunotherapeutics Ltd. has completed a corporate reorganization that separates its contract development and manufacturing activities from its internal research and development operations. The restructuring follows Scinai’s previously announced acquisition of Recipharm Israel Ltd. and is intended to create clearer operational focus across its businesses.
Under the new structure, all CDMO‑related operations, including personnel, infrastructure, manufacturing facilities and customer contracts, have been transferred into a dedicated subsidiary, Scinai Biopharma Services Ltd. The subsidiary is wholly owned by Scinai Immunotherapeutics and operates as a privately held CDMO platform.
Amir Reichman, CEO of Scinai, said, “This reorganization represents a deliberate transformation of how we operate and how we create value. We undertook this restructuring with a clear objective: to position each part of the business more effectively for its respective stakeholders.”
“By consolidating our CDMO activities into a dedicated platform and separating them from our R&D operations, we are aligning our structure with our strategy,” Reichman added. “This allows us to scale the CDMO business as a standalone growth engine while advancing our pipeline in a disciplined and capital-efficient manner.”
Scinai said its CDMO platform combines biologics development, analytical services and aseptic manufacturing capabilities at its Jerusalem site with small‑molecule drug development and manufacturing services at the Yavne facility acquired from Recipharm Israel. In addition, the company maintains a commercial collaboration with Recipharm that provides access to external manufacturing capabilities as an extension of its platform.
The platform is designed to support customer programs across multiple stages of development and manufacturing.
Following the reorganization, Scinai Immunotherapeutics retains a leaner R&D organization focused on advancing its immunology and inflammation programs. The company said the separation is intended to enhance capital efficiency and allow each business unit to pursue its respective priorities through 2026.
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
